Symbols

PHAT

Phathom·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PHAT

Phathom Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing novel treatments for gastrointestinal diseases and disorders

Industry

Pharmaceutical

Established Date

01/09/2018

Listing Date

10/25/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

371

Fiscal Year Ends

12-31

Website

www.phathompharma.com

Security Type

Common stock

Office address

100 Campus Drive , Suite 102 , Florham Park , New Jersey 07932

Business

Introduction

Phathom Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 9, 2018. The Company is a biopharmaceutical company focused on the development and commercialization of new therapies for the treatment of gastrointestinal diseases or GI diseases. The Company's approved products include VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, all of which contain vonoprazan, an oral small molecule potassium ion competitive acid blocker (PCAB). PCAB is a new class of molecules that inhibit gastric acid secretion. VOQUEZNA is currently the only PCAB approved for sale in the United States.

Company Financials

EPS

PHAT has released its 2025 Q4 earnings. EPS was reported at -0.08, versus the expected -0.42, beating expectations. The chart below visualizes how PHAT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PHAT has released its 2025 Q4 earnings report, with revenue of 57.58M, reflecting a YoY change of 94.12%, and net profit of -21.15M, showing a YoY change of 71.59%. The Sankey diagram below clearly presents PHAT's revenue sources and cost distribution.